Overview of Measles Infection and Prevention

Oct 19, 2024

Lecture Notes: Measles

Introduction

  • Highly contagious infectious disease.
  • Leading cause of death, especially among young children in areas with low vaccination rates.
  • Also known as rubeola, not to be confused with German measles (rubella).

Virology

  • Caused by the measles virus, genus Morbillivirus, family Paramyxoviridae.
  • Airborne transmission via tiny liquid particles from sneezes or coughs.
  • Virus can live up to 2 hours in the air or on surfaces.
  • Extremely contagious: 90% infection rate among non-immune close contacts.

Pathogenesis

  • Infects epithelial cells in trachea or bronchi using hemagglutinin (H protein) and other receptors like CD46, CD150 (SLAM), and Nectin-4.
  • Single-stranded RNA virus, negative sense; transcribed by RNA polymerase into mRNA.
  • Spreads to lymph nodes, blood, and other organs like lungs, intestines, and brain.

Clinical Course

  1. Incubation Period: 10-14 days from exposure to symptom onset.
  2. Prodromal Period: Lasts around 3 days; includes high fever, cough, conjunctivitis, choriza.
    • Appearance of Koplik's spots (enanthem) inside cheeks.
  3. Exanthem Phase: Red, blotchy rash spreads from head to extremities; rash fades after about 4 days.
  4. Recovery Phase: Lasts another 10-14 days; final symptom often a persistent cough.
  • Contagious from 4 days before to 4 days after rash onset.
  • Lifelong immunity post-recovery.

Complications

  • Pneumonia, diarrhea, encephalitis.
  • Immune suppression for up to 6 weeks leading to bacterial infections like otitis media.
  • Higher mortality in young infants.
  • Risk of subacute sclerosing panencephalitis (SSPE) 7-10 years post-infection.
  • Immunocompromised individuals may have atypical symptom presentation but higher complication rates.

Diagnosis and Prevention

  • Diagnosed via serology: measles antibodies in blood serum.
  • Disease most common in unvaccinated individuals.
  • Vaccine Information:
    • Live attenuated vaccine given at 12-15 months and 4-6 years.
    • 95% efficacy rate.
    • Maternal antibodies provide protection up to 9 months.

Treatment

  • No specific antiviral treatment.
  • Focus on treating superinfections, maintaining hydration, and pain relief.
  • Vitamin A prescribed to some groups to boost immune response.

Outbreak Management

  • Vaccination for household contacts.
  • Measles immunoglobulin for pregnant women and young infants.

Summary

  • Measles is a highly contagious airborne pathogen.
  • Causes cough, conjunctivitis, choriza, and complications like pneumonia, encephalitis.
  • Preventable through vaccination.